Cargando…

Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection

The SARS-CoV-2 pandemic has focused attention on prevention, restriction and treatment methods that are acceptable worldwide. This means that they should be simple and inexpensive. This review examines the possible role of glycosaminoglycan (GAG) antithrombotics in the treatment of COVID-19. The pat...

Descripción completa

Detalles Bibliográficos
Autor principal: Magnani, Harry N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868468/
https://www.ncbi.nlm.nih.gov/pubmed/33539214
http://dx.doi.org/10.1177/1076029620977702
_version_ 1783648459686936576
author Magnani, Harry N.
author_facet Magnani, Harry N.
author_sort Magnani, Harry N.
collection PubMed
description The SARS-CoV-2 pandemic has focused attention on prevention, restriction and treatment methods that are acceptable worldwide. This means that they should be simple and inexpensive. This review examines the possible role of glycosaminoglycan (GAG) antithrombotics in the treatment of COVID-19. The pathophysiology of this disease reveals a complex interplay between the hemostatic and immune systems that can be readily disrupted by SARS-CoV-2. Some of the GAG antithrombotics also possess immune-modulatory actions and since they are relatively inexpensive they could play an important role in the management of COVID-19 and its complications.
format Online
Article
Text
id pubmed-7868468
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-78684682021-02-19 Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection Magnani, Harry N. Clin Appl Thromb Hemost Review The SARS-CoV-2 pandemic has focused attention on prevention, restriction and treatment methods that are acceptable worldwide. This means that they should be simple and inexpensive. This review examines the possible role of glycosaminoglycan (GAG) antithrombotics in the treatment of COVID-19. The pathophysiology of this disease reveals a complex interplay between the hemostatic and immune systems that can be readily disrupted by SARS-CoV-2. Some of the GAG antithrombotics also possess immune-modulatory actions and since they are relatively inexpensive they could play an important role in the management of COVID-19 and its complications. SAGE Publications 2021-02-04 /pmc/articles/PMC7868468/ /pubmed/33539214 http://dx.doi.org/10.1177/1076029620977702 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Magnani, Harry N.
Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection
title Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection
title_full Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection
title_fullStr Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection
title_full_unstemmed Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection
title_short Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection
title_sort rationale for the role of heparin and related gag antithrombotics in covid-19 infection
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868468/
https://www.ncbi.nlm.nih.gov/pubmed/33539214
http://dx.doi.org/10.1177/1076029620977702
work_keys_str_mv AT magnaniharryn rationalefortheroleofheparinandrelatedgagantithromboticsincovid19infection